ArticleScientific reports2016
Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Exploring translational relevance of baseline and longitudinal metabolic profiling in the blood of ovarian cancer patients.NPJ precision oncology · 2026Article
- A technical review of multi-omics data integration methods: from classical statistical to deep generative approaches.Briefings in bioinformatics · 2025Review
- Aggressive serous ovarian cancer subtype defined by high centrality lncRNA profiles and master transcription factors.Scientific reports · 2025Article
- PartIES: a disease subtyping framework with Partition-level Integration using diffusion-Enhanced Similarities from multi-omics Data.Briefings in bioinformatics · 2024Article
- Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway.Nature communications · 2024Article
- Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.Journal of cancer research and clinical oncology · 2023Article
- The Clinical Significance of Genetic Variation in Ovarian Cancer.International journal of molecular sciences · 2023Article
- Multi-omics-based analysis of high grade serous ovarian cancer subtypes reveals distinct molecular processes linked to patient prognosis.FEBS open bio · 2023Article
- Deep learning in spatial transcriptomics: Learning from the next next-generation sequencing.Biophysics reviews · 2023Review
- CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy.NPJ systems biology and applications · 2022Article
- Immune-and Metabolism-Associated Molecular Classification of Ovarian Cancer.Frontiers in oncology · 2022Article
- Unraveling Autocrine Signaling Pathways through Metabolic Fingerprinting in Serous Ovarian Cancer Cells.Biomedicines · 2021Article
- Tendon and multiomics: advantages, advances, and opportunities.NPJ Regenerative medicine · 2021Review
- Integrated multi-omics analysis of ovarian cancer using variational autoencoders.Scientific reports · 2021Article
- DNA methylation subtypes for ovarian cancer prognosis.FEBS open bio · 2021Article
- Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer.Journal of personalized medicine · 2021Review
- Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer.Scientific reports · 2021Article
- Multi-omic biomarker identification and validation for diagnosing warzone-related post-traumatic stress disorder.Molecular psychiatry · 2020Article
- Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile.International journal of molecular sciences · 2020Article
- Single-cell multiomics: technologies and data analysis methods.Experimental & molecular medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classification of ovarian cancer by morphologic features has a limited effect on serous ovarian cancer (SOC) treatment and prognosis. Here, we proposed a new system for SOC subtyping based on the molecular categories from the Cancer Genome Atlas project. We analyzed the DNA methylation, protein, microRNA, and gene expression of 1203 samples from 599 serous ovarian cancer patients. These samples were divided into nine subtypes based on RNA-seq data, and each subtype was found to be associated with the activation and/or suppression of the following four biological processes: immunoactivity, hormone metabolic, mesenchymal development and the MAPK signaling pathway. We also identified four DNA methylation, two protein expression, six microRNA sequencing and four pathway subtypes. By integrating the subtyping results across different omics platforms, we found that most RNA-seq subtypes overlapped with one or two subtypes from other omics data. Our study sheds light on the molecular mechanisms of SOC and provides a new perspective for the more accurate stratification of its subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.